Scleroderma renal crisis in a Swedish systemic sclerosis cohort: Survival, renal outcome, and RNA polymerase III antibodies as a risk factor

Scandinavian Journal of Rheumatology

Volumn 41, Issue 1, 2012, Pages 39-43

  Hesselstrand, R ^a   Scheja, A ^a   Wuttge, D M ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RNA POLYMERASE III ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOANALYSIS; BLOOD SAMPLING; BONE NECROSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; ENZYME IMMUNOASSAY; FEMALE; FLUOROENZYME IMMUNOASSAY; HEMODIALYSIS; HIP OSTEONECROSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCLERODERMA RENAL CRISIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; SWEDEN;

EID: 84856466047     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.610032     Document Type: Article

References (21)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
2. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
3. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis1998;57:682-6. (Pubitemid 28558973)
4. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med1992;82:139-48.
5. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003;42:71-5. (Pubitemid 36131570)
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
7. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med 2007;100:485-94. (Pubitemid 47241915)
8. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford) 2009;48:1570-4.
9. Meyer O, de Chaisemartin L, Nicais-Roland P, Cabane J, Tubach F, Dieude P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010;37:125-20.
10. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9. (Pubitemid 46106569)
11. Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, et al. Low prevalence of anti-RNA polymerase III antibodies in French scleroderma population. Eur J Intern Med 2010;21:114-17.
12. Codullo V, Cavazza I, Bonino C, Alpini C, Cavagna L, Cozzi F, et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009;36:1464-9.
13. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
14. Trang G, Steele R, Baron M. Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. Published online 4 December 2010. doi:10.1007/s00296-010-1697-6.
15. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42:534-40. (Pubitemid 36432472)
16. Hesselstrand R, Wuttge DM, Wildt M, Ekmehag B, Scheja A. Survival in patients with pulmonary arterial hypertension associated with connective tissue disease from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011;40:127-32.
17. Nguyen B, Mayes MD, Arnett FC, del Junco D, Reveille JD, Gonzalez EB, et al. HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011;63:530-4.
18. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399-404. (Pubitemid 23127339)
19. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
20. Scheja A, Bartosik I, Wuttge DM, Hesselstrand. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009;38:295-8.
21. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)